Hemorrhagic stroke - investigations

The investigation of hemorrhagic stroke is a multi-faceted process involving rapid clinical assessment, neuroimaging (primarily CT and CTA), and laboratory studies to identify the cause, extent, and complications of the bleed. The goal is to differentiate hemorrhagic from ischemic stroke, identify the source of the bleed, rule out mimics, and guide appropriate management strategies to minimize secondary brain injury and improve patient outcomes.

Note 1: Initial Assessment and Stabilization: The immediate focus in a suspected hemorrhagic stroke is on stabilizing the patient and performing a rapid neurological assessment. This involves assessing the patient's level of consciousness using tools like the Glasgow Coma Scale (GCS), evaluating vital signs (blood pressure, heart rate, respiratory rate, and oxygen saturation), and performing a brief neurological examination to identify any obvious deficits (e.g., hemiparesis, aphasia). Elevated blood pressure is common in hemorrhagic stroke and is often addressed cautiously, as overly aggressive reduction can compromise cerebral perfusion, but uncontrolled hypertension can exacerbate bleeding. Securing the airway and ensuring adequate oxygenation are paramount. A common misconception is that all patients with elevated blood pressure need immediate and drastic reduction; the goal is controlled reduction within a specific range guided by established guidelines to avoid harming the brain.

Note 2: Non-Contrast Computed Tomography (NCCT): NCCT is the primary and most readily available imaging modality for the initial evaluation of suspected hemorrhagic stroke. It can quickly detect the presence of blood within the brain parenchyma, ventricles, or subarachnoid space. NCCT also helps to exclude other conditions that can mimic stroke symptoms, such as tumors or subdural hematomas. The sensitivity of NCCT for detecting acute hemorrhage is very high, approaching 95% within the first 24 hours. However, small hemorrhages or those in the posterior fossa may be more difficult to visualize, and repeat imaging may be necessary. The practical application of NCCT is in differentiating between ischemic and hemorrhagic stroke, which is crucial for determining the appropriate treatment strategy. NCCT does not typically visualize aneurysms or arteriovenous malformations, which may require further imaging.

Note 3: Computed Tomography Angiography (CTA): CTA is a valuable adjunct to NCCT in the evaluation of hemorrhagic stroke. It involves injecting a contrast agent into the bloodstream and acquiring CT images during the arterial phase. CTA can identify potential sources of bleeding, such as aneurysms, arteriovenous malformations (AVMs), or dural arteriovenous fistulas (dAVFs). It can also help assess the extent of cerebral vasospasm, a common complication of subarachnoid hemorrhage. CTA should be performed in patients with suspected aneurysmal subarachnoid hemorrhage or in those with intracerebral hemorrhage where a secondary cause is suspected (e.g., young patients, atypical location). The timing of CTA is important; it is usually performed after the initial NCCT demonstrates hemorrhage. Misconception: CTA is only for subarachnoid hemorrhage. It is also helpful for ICH with suspected underlying vascular malformation.

Note 4: Magnetic Resonance Imaging (MRI): MRI is a more sensitive imaging modality than CT for detecting subtle brain abnormalities, particularly in the posterior fossa and brainstem. MRI sequences such as gradient-echo (GRE) or susceptibility-weighted imaging (SWI) are highly sensitive to blood products and can detect small hemorrhages that may be missed on NCCT. MRI can also provide information about the age of the hemorrhage and identify underlying structural lesions. However, MRI is not always readily available in the acute setting, and it is contraindicated in some patients (e.g., those with certain metallic implants). MRI is often used as a second-line imaging modality in patients with suspected stroke, particularly when the diagnosis is uncertain or when further characterization of the lesion is needed. Diffusion-weighted imaging (DWI) can also help exclude concurrent ischemic stroke.

Note 5: Lumbar Puncture (LP): Lumbar puncture is indicated when subarachnoid hemorrhage is suspected but the initial NCCT is negative. Xanthochromia (yellow discoloration of the cerebrospinal fluid) is a key finding that indicates the presence of blood breakdown products. LP should be performed at least 12 hours after the onset of symptoms to allow for sufficient time for xanthochromia to develop. Before performing LP, it is essential to rule out any contraindications, such as increased intracranial pressure or a mass lesion, to avoid the risk of brain herniation. LP is also useful in excluding meningitis or other infectious causes of neurological symptoms. A common misconception is that LP is always necessary when SAH is suspected; it's only needed if the CT scan is negative.

Note 6: Cerebral Angiography (Catheter Angiography or DSA): Cerebral angiography, also known as digital subtraction angiography (DSA), is the gold standard for visualizing cerebral vasculature and identifying aneurysms, AVMs, and other vascular abnormalities. It involves inserting a catheter into an artery (usually the femoral artery) and injecting contrast dye into the cerebral vessels. DSA provides high-resolution images and allows for detailed assessment of vascular anatomy. While CTA is often used as a screening tool, DSA is typically reserved for cases where CTA findings are inconclusive or when intervention (e.g., coiling or clipping of an aneurysm) is planned. DSA is an invasive procedure with potential risks, such as stroke or arterial injury, so it should be performed by experienced interventional neuroradiologists.

Note 7: Electrocardiogram (ECG) and Cardiac Monitoring: ECG and cardiac monitoring are essential components of the evaluation of hemorrhagic stroke. Atrial fibrillation is a common risk factor for cardioembolic stroke, and it can also be associated with hemorrhagic transformation after ischemic stroke. ECG can detect arrhythmias or other cardiac abnormalities that may contribute to stroke. Cardiac monitoring can help identify intermittent arrhythmias or other cardiac events that may be missed on a single ECG. In patients with subarachnoid hemorrhage, ECG changes such as ST-segment elevation or T-wave inversion may occur due to catecholamine release from the hypothalamus. These changes can mimic acute myocardial infarction and should be interpreted with caution. Practical application: guide anticoagulation decisions.

Note 8: Coagulation Studies and Blood Tests: Coagulation studies, including prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time (PTT), are crucial for assessing the patient's coagulation status. These tests can help identify underlying bleeding disorders or the use of anticoagulant medications (e.g., warfarin, heparin). A complete blood count (CBC) can assess for thrombocytopenia or other hematological abnormalities. Serum electrolytes and renal function tests are also important to evaluate for metabolic disturbances that can affect neurological function. Liver function tests can help identify underlying liver disease, which can impair coagulation. Blood glucose levels should be monitored to exclude hypoglycemia or hyperglycemia, which can mimic stroke symptoms. The purpose is to exclude other causes or complications and to guide potential reversal of anticoagulation.

Note 9: Transcranial Doppler (TCD): TCD is a non-invasive ultrasound technique used to measure blood flow velocity in the major cerebral arteries. It is particularly useful in detecting and monitoring cerebral vasospasm after subarachnoid hemorrhage. Vasospasm can lead to delayed cerebral ischemia and neurological deterioration. TCD can also be used to assess cerebral autoregulation and identify patients at risk for hypoperfusion. TCD findings are often correlated with clinical findings and other imaging modalities, such as CTA. TCD is operator-dependent, and its accuracy can be affected by factors such as skull thickness and patient cooperation. Serial TCD studies are often performed to monitor for changes in blood flow velocity.

Note 10: Blood Pressure Management Considerations: Blood pressure management in hemorrhagic stroke is complex and requires careful consideration of the patient's individual circumstances. While elevated blood pressure is common, overly aggressive reduction can compromise cerebral perfusion and worsen outcomes. Current guidelines recommend maintaining systolic blood pressure (SBP) within a specific range, often between 140-160 mmHg, while closely monitoring neurological status. Antihypertensive medications such as labetalol or nicardipine are commonly used. In patients with subarachnoid hemorrhage, maintaining adequate cerebral perfusion pressure (CPP) is crucial to prevent delayed cerebral ischemia. The target CPP is typically above 70 mmHg. Close monitoring of blood pressure and neurological status is essential to optimize outcomes. A common misconception is that lower blood pressure is always better after a hemorrhagic stroke. Gradual and controlled reduction is key.

Note 11: Rule out Hemorrhagic Conversion of Ischemic Stroke: In patients presenting with suspected acute stroke, it is essential to differentiate between primary hemorrhagic stroke and hemorrhagic conversion of an ischemic stroke. Hemorrhagic conversion can occur after thrombolytic therapy (e.g., alteplase) or endovascular thrombectomy. Imaging findings, clinical history, and timing of symptom onset are crucial for distinguishing these two entities. Hemorrhagic conversion is more likely in patients with large infarcts or those who have received thrombolytic therapy. If hemorrhagic conversion is suspected, anticoagulation should be immediately discontinued, and appropriate management strategies should be implemented. Early recognition and management are critical to minimizing the risk of neurological deterioration. This consideration is particularly relevant in patients presenting outside the typical timeframe for thrombolysis for unknown time of onset strokes.

Note 12: Detailed Neurological Exam: Beyond the GCS, a complete neurological exam should assess cranial nerve function, motor strength and coordination, sensory function, reflexes, and cerebellar function. Serial neurological exams are critical to monitor for any changes in the patient's condition. Worsening neurological deficits may indicate expanding hematoma, increased intracranial pressure, or vasospasm. The National Institutes of Health Stroke Scale (NIHSS) is a standardized assessment tool used to quantify neurological deficits and monitor changes over time. Documenting the details of the neurological exam is essential for guiding treatment decisions and assessing prognosis. Use clear and precise language when describing findings (e.g., "3/5 strength in the left upper extremity" rather than "mild weakness"). The exam helps to establish a baseline and track the patient's progress or decline over time.

Browse public study notes